Clinical characteristics and outcomes of COVID-19 infection in Chinese patients with hematologic malignancies in the Omicron era
ABSTRACTPatients with hematologic malignancies are often immunodeficient and therefore have a higher risk of severe symptoms from coronavirus disease 2019 (COVID-19). We retrospectively examined a cohort of 289 patients from 16 hospitals in Zhejiang Province who had hematologic malignancies and COVI...
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-12-01
|
| Series: | Hematology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/16078454.2023.2288477 |
| _version_ | 1827620218266976256 |
|---|---|
| author | Xian Li Aiqi Zhao Huifang Jiang Ying Lu Jing Le Yaping Xie Meiwei Hu Hui Zeng Jianzhi Zhao Mei Zhou Hui Zhou Lili Chen Weiguo Zhu Guifang Ouyang Huiqing Qiu Songfu Jiang Qunyi Guo Wenbin Qian Yun Liang |
| author_facet | Xian Li Aiqi Zhao Huifang Jiang Ying Lu Jing Le Yaping Xie Meiwei Hu Hui Zeng Jianzhi Zhao Mei Zhou Hui Zhou Lili Chen Weiguo Zhu Guifang Ouyang Huiqing Qiu Songfu Jiang Qunyi Guo Wenbin Qian Yun Liang |
| author_sort | Xian Li |
| collection | DOAJ |
| description | ABSTRACTPatients with hematologic malignancies are often immunodeficient and therefore have a higher risk of severe symptoms from coronavirus disease 2019 (COVID-19). We retrospectively examined a cohort of 289 patients from 16 hospitals in Zhejiang Province who had hematologic malignancies and COVID-19 during a period when the Omicron variant was predominant. Univariate analysis showed that some clinical characteristics, including elder age (P = 0.014), multiple comorbid conditions (P = 0.011), and receipt of active antineoplastic therapy (P = 0.018) were associated with an increased risk of severe COVID-19. Patients with severe/critical COVID-19 had significantly lower levels of lymphocytes and serum albumin, and significantly higher levels of D-dimer, lactate dehydrogenase, C-reactive protein, and interleukin-6 (all P < 0.05). Fifty-four patients (18.7%) had symptoms lasting ≥3 weeks, suggesting that persistent long-term COVID-19 infection is likely present in a significant proportion of patients. Receipt of the inactivated vaccine was unrelated to disease severity (P = 0.143), which indicated that many patients with hematologic malignancies may not have effective humoral immunity to inactivated vaccines. |
| first_indexed | 2024-03-09T10:44:33Z |
| format | Article |
| id | doaj.art-8012ab8e66364dff8a566fa78cd798c5 |
| institution | Directory Open Access Journal |
| issn | 1607-8454 |
| language | English |
| last_indexed | 2024-03-09T10:44:33Z |
| publishDate | 2023-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Hematology |
| spelling | doaj.art-8012ab8e66364dff8a566fa78cd798c52023-12-01T11:16:48ZengTaylor & Francis GroupHematology1607-84542023-12-0128110.1080/16078454.2023.2288477Clinical characteristics and outcomes of COVID-19 infection in Chinese patients with hematologic malignancies in the Omicron eraXian Li0Aiqi Zhao1Huifang Jiang2Ying Lu3Jing Le4Yaping Xie5Meiwei Hu6Hui Zeng7Jianzhi Zhao8Mei Zhou9Hui Zhou10Lili Chen11Weiguo Zhu12Guifang Ouyang13Huiqing Qiu14Songfu Jiang15Qunyi Guo16Wenbin Qian17Yun Liang18Department of Hematology, The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, People’s Republic of ChinaDepartment of Hematology, The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, People’s Republic of ChinaDepartment of Hematology, TongDe Hospital of Zhejiang Province, Hangzhou, People’s Republic of ChinaDepartment of Hematology, The Affiliated People’s Hospital of Ningbo University, Ningbo, People’s Republic of ChinaDepartment of Hematology, Ningbo Medical Center Li Huili Hospital, Ningbo, People’s Republic of ChinaDepartment of Hematology, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou, People’s Republic of ChinaDepartment of Hematology, The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, People’s Republic of ChinaDepartment of Hematology, The First Affiliated Hospital of Jiaxing University, Jiaxing, People’s Republic of ChinaDepartment of Hematology, Shaoxing Center Hospital, Shaoxing, People’s Republic of ChinaDepartment of Hematology, Zhuji People’s Hospital, Zhuji, People’s Republic of ChinaDepartment of Hematology, The Affiliated Hospital of Hangzhou Normal University, Hangzhou, People’s Republic of ChinaDepartment of Medical Oncology, Taizhou First People’s Hospital, Taizhou, People’s Republic of ChinaDepartment of Hematology, Shaoxing Second Hospital, Shaoxing, People’s Republic of ChinaDepartment of Hematology, Ningbo First Hospital, Ningbo, People’s Republic of ChinaDepartment of Hematology and Medical Oncology, The Second People’s Hospital of Quzhou, Quzhou, People’s Republic of ChinaDepartment of Hematology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, People’s Republic of ChinaDepartment of Hematology and Medical Oncology, Enze Medical Center, Taizhou, People’s Republic of ChinaDepartment of Hematology, The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, People’s Republic of ChinaDepartment of Hematology, The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, People’s Republic of ChinaABSTRACTPatients with hematologic malignancies are often immunodeficient and therefore have a higher risk of severe symptoms from coronavirus disease 2019 (COVID-19). We retrospectively examined a cohort of 289 patients from 16 hospitals in Zhejiang Province who had hematologic malignancies and COVID-19 during a period when the Omicron variant was predominant. Univariate analysis showed that some clinical characteristics, including elder age (P = 0.014), multiple comorbid conditions (P = 0.011), and receipt of active antineoplastic therapy (P = 0.018) were associated with an increased risk of severe COVID-19. Patients with severe/critical COVID-19 had significantly lower levels of lymphocytes and serum albumin, and significantly higher levels of D-dimer, lactate dehydrogenase, C-reactive protein, and interleukin-6 (all P < 0.05). Fifty-four patients (18.7%) had symptoms lasting ≥3 weeks, suggesting that persistent long-term COVID-19 infection is likely present in a significant proportion of patients. Receipt of the inactivated vaccine was unrelated to disease severity (P = 0.143), which indicated that many patients with hematologic malignancies may not have effective humoral immunity to inactivated vaccines.https://www.tandfonline.com/doi/10.1080/16078454.2023.2288477COVID-19hematologic malignancyChinesesevere infectionclinical characteristicsoutcome |
| spellingShingle | Xian Li Aiqi Zhao Huifang Jiang Ying Lu Jing Le Yaping Xie Meiwei Hu Hui Zeng Jianzhi Zhao Mei Zhou Hui Zhou Lili Chen Weiguo Zhu Guifang Ouyang Huiqing Qiu Songfu Jiang Qunyi Guo Wenbin Qian Yun Liang Clinical characteristics and outcomes of COVID-19 infection in Chinese patients with hematologic malignancies in the Omicron era Hematology COVID-19 hematologic malignancy Chinese severe infection clinical characteristics outcome |
| title | Clinical characteristics and outcomes of COVID-19 infection in Chinese patients with hematologic malignancies in the Omicron era |
| title_full | Clinical characteristics and outcomes of COVID-19 infection in Chinese patients with hematologic malignancies in the Omicron era |
| title_fullStr | Clinical characteristics and outcomes of COVID-19 infection in Chinese patients with hematologic malignancies in the Omicron era |
| title_full_unstemmed | Clinical characteristics and outcomes of COVID-19 infection in Chinese patients with hematologic malignancies in the Omicron era |
| title_short | Clinical characteristics and outcomes of COVID-19 infection in Chinese patients with hematologic malignancies in the Omicron era |
| title_sort | clinical characteristics and outcomes of covid 19 infection in chinese patients with hematologic malignancies in the omicron era |
| topic | COVID-19 hematologic malignancy Chinese severe infection clinical characteristics outcome |
| url | https://www.tandfonline.com/doi/10.1080/16078454.2023.2288477 |
| work_keys_str_mv | AT xianli clinicalcharacteristicsandoutcomesofcovid19infectioninchinesepatientswithhematologicmalignanciesintheomicronera AT aiqizhao clinicalcharacteristicsandoutcomesofcovid19infectioninchinesepatientswithhematologicmalignanciesintheomicronera AT huifangjiang clinicalcharacteristicsandoutcomesofcovid19infectioninchinesepatientswithhematologicmalignanciesintheomicronera AT yinglu clinicalcharacteristicsandoutcomesofcovid19infectioninchinesepatientswithhematologicmalignanciesintheomicronera AT jingle clinicalcharacteristicsandoutcomesofcovid19infectioninchinesepatientswithhematologicmalignanciesintheomicronera AT yapingxie clinicalcharacteristicsandoutcomesofcovid19infectioninchinesepatientswithhematologicmalignanciesintheomicronera AT meiweihu clinicalcharacteristicsandoutcomesofcovid19infectioninchinesepatientswithhematologicmalignanciesintheomicronera AT huizeng clinicalcharacteristicsandoutcomesofcovid19infectioninchinesepatientswithhematologicmalignanciesintheomicronera AT jianzhizhao clinicalcharacteristicsandoutcomesofcovid19infectioninchinesepatientswithhematologicmalignanciesintheomicronera AT meizhou clinicalcharacteristicsandoutcomesofcovid19infectioninchinesepatientswithhematologicmalignanciesintheomicronera AT huizhou clinicalcharacteristicsandoutcomesofcovid19infectioninchinesepatientswithhematologicmalignanciesintheomicronera AT lilichen clinicalcharacteristicsandoutcomesofcovid19infectioninchinesepatientswithhematologicmalignanciesintheomicronera AT weiguozhu clinicalcharacteristicsandoutcomesofcovid19infectioninchinesepatientswithhematologicmalignanciesintheomicronera AT guifangouyang clinicalcharacteristicsandoutcomesofcovid19infectioninchinesepatientswithhematologicmalignanciesintheomicronera AT huiqingqiu clinicalcharacteristicsandoutcomesofcovid19infectioninchinesepatientswithhematologicmalignanciesintheomicronera AT songfujiang clinicalcharacteristicsandoutcomesofcovid19infectioninchinesepatientswithhematologicmalignanciesintheomicronera AT qunyiguo clinicalcharacteristicsandoutcomesofcovid19infectioninchinesepatientswithhematologicmalignanciesintheomicronera AT wenbinqian clinicalcharacteristicsandoutcomesofcovid19infectioninchinesepatientswithhematologicmalignanciesintheomicronera AT yunliang clinicalcharacteristicsandoutcomesofcovid19infectioninchinesepatientswithhematologicmalignanciesintheomicronera |